Allergic bronchopulmonary Aspergillosis in children

Area of Science:

• Pediatric Allergy and Immunology
• Pulmonology
• Clinical Medicine

Background:

• Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease caused by Aspergillus fumigatus.
• Current diagnostic criteria, staging, and treatments for ABPA are primarily based on adult studies.
• Pediatric-specific data on ABPA diagnosis and treatment is limited, necessitating further research.

Purpose of the Study:

• To evaluate the applicability of existing ABPA diagnostic criteria in pediatric patients.
• To assess the efficacy of alternative treatment regimens beyond oral corticosteroids for pediatric ABPA.
• To analyze treatment-related changes and outcomes in children diagnosed with ABPA.

Main Methods:

• Retrospective analysis of pediatric patients diagnosed with ABPA between January 2017 and 2020.
• Inclusion of demographic data, clinical and laboratory findings, diagnostic scores, and treatment protocols.
• Review of high-resolution computed tomography (HRCT) for bronchiectasis and spirometry for treatment response.

Main Results:

• The mean age of pediatric ABPA patients was 14.33 ± 1.96 years.
• Median total IgE was 1033 IU/mL and median Aspergillus fumigatus specific IgE was 10.64 kU/L at diagnosis.
• Bronchiectasis was observed in 5 cases; omalizumab showed significant spirometric improvement in a patient with steroid complications.

Conclusions:

• Clear diagnostic and treatment algorithms for pediatric ABPA are essential.
• Further research is needed to establish pediatric-specific guidelines to prevent lung damage and minimize drug side effects.
• Investigating risk factors for ABPA in children remains an ongoing challenge.